Drugs / JS007
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05049265 | Nov 2021 → Sep 2022 | — | Shanghai Junshi Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06370754 | Apr 2024 → Apr 2026 overdue | malignant pancreatic neoplasm | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06954467 | May 2025 → Dec 2027 expected | hepatocellular carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07823348 | Oct 2026 → Oct 2029 expected | hepatocellular carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06954467 ↗ |
| Action | Inhibit | “Blocking cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)” PMID 39354625 ↗ Oct 2024 |
| Modality | Monoclonal antibody | “CTLA-4 monoclonal antibody” NCT07823348 ↗ |
| Route | Intravenous | “JS007 was administered intravenously every 3 weeks at doses of 0.03, 0.3, 1, 3, and 10 mg/kg” PMID 39354625 ↗ Oct 2024 |
| Target | CTLA4 | “Blocking cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)” PMID 39354625 ↗ Oct 2024 |